Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
Provided By GlobeNewswire
Last update: Feb 27, 2025
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)
On-track to enable dosing ALS patients in 2025
Read more at globenewswire.comNASDAQ:ATHA (10/22/2025, 3:00:52 PM)
3.8701
-0.39 (-9.15%)
Find more stocks in the Stock Screener
